Dr. Stephen Mullin of the University of Plymouth talks for The Cure Parkinson’s Trust about the research into GBA Parkinson’s and the current convergent studies which all seem to be pointing towards GBA. In terms of the prospects to develop drugs to slow the development of PD, GBA is the most advanced. The next phase will be identifying PD patients who are carriers of the mutations in the GBA gene and beginning clinical human trials. Simultaneously there needs to be research into how GBA causes PD in humans. The prospects for ambroxol as a disease modifying agent in GBA PD are strong. Ambroxol has already been used by many patients and may be able to reverse some of the effects that lead to PD.